June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Hammerhead ribozyme in a tRNA scaffold: Effects of RNA processing and anti-sense flank length on cleavage in-vivo
Author Affiliations & Notes
  • Jason Myers
    Research Service, VA Western NY Healthcare System, Buffalo, New York, United States
    Ophthalmology (Ross Eye Institute), University at Buffalo-SUNY, Buffalo, New York, United States
  • Zahra Fayazi
    Ophthalmology (Ross Eye Institute), University at Buffalo-SUNY, Buffalo, New York, United States
  • Mark Christian Butler
    Research Service, VA Western NY Healthcare System, Buffalo, New York, United States
    Ophthalmology (Ross Eye Institute), University at Buffalo-SUNY, Buffalo, New York, United States
  • Jack M Sullivan
    Research Service, VA Western NY Healthcare System, Buffalo, New York, United States
    Ophthalmology (Ross Eye Institute), Pharmacology/Toxicology, Physiology/Biophysics and Program in Neuroscience, University at Buffalo-SUNY, Buffalo, New York, United States
  • Footnotes
    Commercial Relationships   Jason Myers, None; Zahra Fayazi, None; Mark Butler, None; Jack Sullivan, Research Foundation of SUNY (P)
  • Footnotes
    Support  NIH/NEI R01EY013433 (JMS); Veterans Administration Merit Award 1I01 BX000669 (JMS); SUNY Health Now Award (JMS); Research to Prevent Blindness Unrestricted Award (Univ. Buffalo)
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4496. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jason Myers, Zahra Fayazi, Mark Christian Butler, Jack M Sullivan; Hammerhead ribozyme in a tRNA scaffold: Effects of RNA processing and anti-sense flank length on cleavage in-vivo. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4496.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Embed a therapeutic hammerhead ribozyme (hhRz) within a human tRNA-Lys3 scaffold and screen modifications to achieve and optimize a gene therapy agent for Stargardt/dry AMD/adRP by suppression of human rod rhodopsin (hRHO).

Methods : tRNA hhRz processing and mRNA were assayed by endpoint RT/PCR and real time RT/PCR. hRHO knockdown by various 725 hhRzs and varying anti-sense (AS) flank lengths was assayed by RT/PCR, Alexa-647-1D4 IHC , and a reporter from a bicistronic construct (phRHO-IRES-SuperNova). HhRz kinetic model of Stage-Zimmermann and Uhlenbeck (1998) and RNAstructure were used for modelling.

Results : tRNAs are transcribed by RNA Pol III, but addition of an upstream H1 promoter/enhancer increases tRNA levels substantially. Fractionation and RNA isolation from H1 tRNA hhRz transfected cells with a 3’ CCA lead to loss of hhRz during processing, while lack of 3’ CCA allows nuclear export where the tRNA hhRz reaches a cytoplasmic steady-state (SS) concentration which modulates collision frequency with hRHO mRNA. When SS is reached cleavage efficiency depends on the hhRz enzyme kinetics which are influenced by the length of the hhRz AS flanks. Kinetic modelling of our initial hhRz with 11 nt 5’ and 7 nt 3’ AS flanks predicted reaction kinetics with a lack of binding specificity (Kbinding = 1.74E-17 M) and product inhibition (product leaving rates of 6.67E-4 min-1 and 2.1 min-1). In transfected cells this tRNA hhRz led to an increase in hRHO levels (mRNA, protein) compared to tRNA scaffold alone (p=0.01009). Decreasing 725 AS flanks to 7/7, 6/6 and 5/5 dropped RHO levels significantly (>50%) compared to Scaffold (7/7 p=0.02072, 6/6 p=1.42E-5, 5/5 p=1.16E-4). Our new lead candidate H1 725 6/6 -CCA had a binding affinity of 0.49 nM and leaving rates of 5 min-1 and 17.8 min -1 which provides specificity without product inhibition. Using Supernova as a reporter for hhRz cleavage, H1 tRNA 725 6/6 –CCA suppressed fluorescence levels by 72% compared to scaffold (p=3.25E-52).

Conclusions : A therapeutic 725 hhRz driven by the H1 promoter/enhancer with 6nt/6nt AS flanks suppresses levels of membrane bound hRHO protein by 50% in transient transfection experiments. This tRNA hhRz delivered by AAV to photoreceptors has potential to rescue light-induced damage of the ABCA4/RDH8 double knockout mouse (Stargardt, dAMD model) and intrinsic retinal degeneration in our humanized adRP hRHO mouse.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×